- Home
- GDEN vs ABUS Comparison
GDEN vs ABUS Comparison
Compare GDEN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEN | ABUS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.2M | 888.5M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | GDEN | ABUS |
|---|---|---|
| Price | $27.02 | $4.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $32.25 | $5.00 |
| AVG Volume (30 Days) | 295.6K | ★ 1.6M |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $643,485,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $1.94 | N/A |
| P/E Ratio | $134.81 | ★ N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $19.57 | $2.71 |
| 52 Week High | $35.49 | $5.10 |
Technical Indicators
Market Signals| Indicator | GDEN | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 41.43 |
| Support Level | $27.03 | $3.99 |
| Resistance Level | $27.82 | $4.33 |
| Average True Range (ATR) | 0.52 | 0.23 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 10.77 | 42.02 |
Price Performance
Historical ComparisonAbout GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.